AVEO Pharmaceuticals – Consensus Indicates Potential 31.6% Upside

Broker Ratings

AVEO Pharmaceuticals found using ticker (AVEO) now have 4 analysts covering the stock with the consensus suggesting a rating of ‘Strong_Buy’. The target price ranges between 17 and 9 with a mean TP of 12. With the stocks previous close at 9.12 this indicates there is a potential upside of 31.6%. The 50 day MA is 7.42 and the 200 moving average now moves to 5.9. The market cap for the company is $275m. Visit the company website at: http://www.aveooncology.com

AVEO Pharmaceuticals, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical needs. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase III TIVO-3 trial of tivozanib for the treatment of RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination with Opdivo (nivolumab), an immune checkpoint (PD-1) inhibitor for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent hepatocyte growth factor inhibitory antibody that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, acute myeloid leukemia, and pancreatic cancer; and AV-203, a potent anti-ErbB3 specific monoclonal antibody, which has completed Phase I clinical trial for treating esophageal cancer. The company’s preclinical stage products include AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 for the treatment of pulmonary arterial hypertension. AVEO Pharmaceuticals has collaboration and license agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix; St. Vincent’s Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Kirin Co., Ltd. It has a clinical collaboration with AstraZeneca PLC to evaluate IMFINZI (durvalumab), a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The company was formerly known as GenPath Pharmaceuticals and changed its name to AVEO Pharmaceuticals in March 2005. AVEO Pharmaceuticals was incorporated in 2001 and is headquartered in Boston, Massachusetts.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit

AIM All Share Index